论文部分内容阅读
为估价秋水仙硷治疗肝硬变的作用,我们对100例肝硬变病人进行随机、双盲、安慰剂对照试验,并随访14年,剂量为每日1mg,每周5天。其中45例为酒精性肝硬变,41例为肝炎后肝硬变,其余14例为各种其他原因所致的肝硬变。92%的病人经过组织学检查。73例为child—Turcotte分类A级,26例为B级,1例C级。54例接受秋水仙硷,46例只用安慰剂。秋水仙硷组总的生存期明显地长于安慰剂组(中线生存期分别为11和3.5年,P<0.001)。秋水仙硷组的累计5年生存率为75%,而安
To assess the role of colchicine in the treatment of cirrhosis, we conducted a randomized, double-blind, placebo-controlled trial of 100 cirrhotic patients for 14 years at a dose of 1 mg daily for 5 days. Of these, 45 were alcoholic cirrhosis, 41 were posthepatitic cirrhosis, and the remaining 14 were cirrhosis due to various other causes. 92% of patients undergo histological examination. 73 cases were classified as child-Turcotte class A, 26 cases were class B, and 1 case was C-class. 54 received colchicine and 46 received placebo. Colchicine total survival was significantly longer than placebo (median survival were 11 and 3.5 years, P <0.001). Colchicine group cumulative 5-year survival rate was 75%, and Ann